---
title: 'Funding Daily Summary: What Happened on November 17, 2026'
headline: Commit raises $60 million to advance complement immunotherapy
description: The seed round will fund preclinical work and regulatory preparations
  for COM002, which the company plans to take into clinical trials.
url: https://thebench.bio/news/funding/2026-11-17
topic: funding
date: '2026-11-17'
covers:
- '2026-11-17'
date_published: '2026-11-17T12:02:19Z'
date_modified: '2026-11-17T12:02:19Z'
tags:
- Industry
sources: 1
publisher: TheBench.Bio
---

# Funding Daily Summary: What Happened on November 17, 2026

**Commit raises $60 million to advance complement immunotherapy**

The seed round will fund preclinical work and regulatory preparations for COM002, which the company plans to take into clinical trials.

## Today in brief

Commit Biologics raised $60 million in a seed round led by Ackermans & van Haaren, with Novo Holdings, Bioqube Ventures and Korys participating and AbbVie Ventures and M Ventures joining its shareholder base. [1] The company plans to prepare COM002 for clinical testing and aims to dose its first patient in early 2028. [1]

## Commit raises $60 million for COM002

Commit Biologics raised $60 million to advance COM002, its complement-based immunotherapy candidate. [1] Ackermans & van Haaren led the seed round. Existing investors Novo Holdings, Bioqube Ventures and Korys also participated. [1] AbbVie Ventures and M Ventures joined the company’s shareholder base through the financing. [1]

Commit said it will use the proceeds for studies needed before clinical testing and to prepare regulatory filings for COM002. [1] The company aims to dose its first patient in early 2028. [1]

Commit reported that COM002 depleted B cells more effectively than an approved T-cell engager in human whole-blood experiments. [1] In a separate nonhuman-primate study, one dose kept B-cell depletion going for more than four weeks, with no cytokine release or treatment-related safety findings reported by the company. [1] These findings are preclinical and do not establish how the candidate will perform or whether it will be safe in patients. [1]

## The day in numbers

- **$60 million**: Commit Biologics’ seed financing to advance COM002 and prepare for clinical testing. [1]
- **Early 2028**: Commit’s target for dosing the first patient with COM002. [1]

## Sources

1. [Commit Biologics secures $60M to advance complement-based immunotherapies](<https://european-biotechnology.com/latest-news/commit-biologics-secures-60m-to-advance-complement-based-immunotherapies/>), European Biotechnology, 2026-11-17

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://european-biotechnology.com/latest-news/commit-biologics-secures-60m-to-advance-complement-based-immunotherapies/>
